A combination of proprietary technology innovations can significantly reduce development-to-production timescales
Honeywell recently announced Fast Track Automation, a combination of proprietary technology innovations for the life sciences industry that enables vital vaccines, treatments and therapies to move from regulatory approval to full production in as little as two months depending on process requirements.
The solution incorporates process automation elements that can be configured in a virtual environment; then implemented rapidly once a therapy is approved and ready to be produced for public distribution.
Fast Track Automation is a response to the global Covid-19 outbreak, which has highlighted the need to accelerate delivery of medical solutions and devices to patients by focusing on ensuring more efficient production and testing capabilities along with facilitating strengthened supply chain.
“Honeywell has provided the life sciences industry with consistently innovative advancements in automation technologies, systems and services for over 30 years, and Fast Track Automation offering is one of our most valuable offerings to date,” said Cynthia Pussinen, VP and General Manager, Life Sciences, Honeywell Process Solutions.
Fast Track Automation leverages the power of the cloud, virtualization, batch software running in the controller, flexible assignment of computing power, remote asset management from a data center, and efficient, fast-track lean project implementation.
The technology prepares manufacturing automation designs in parallel with clinical trials to ensure production is ready to go once a medical therapy is approved.
